mTOR and cancer: insights into a complex relationship

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216

Upstream and downstream of mTOR

Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181

TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival

Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083

mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery

Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051

Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton

Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561

Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB

Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097

Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control

Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

Cytoplasmic RNA-Binding Proteins and the Control of Complex Brain FunctionPreprint

Darnell, J. C., & Richter, J. D. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012344 · Cited by 127

CDK1 substitutes for mTOR kinase to activate mitotic cap-dependent protein translation

Shuda, M., Velásquez, C., Cheng, E., Cordek, D. G., Kwun, H. J., Chang, Y., & Moore, P. S. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505787112 · Cited by 131

Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

Zitzmann, K., von Rüden, J., Brand, S., Göke, B., Lichtl, J., Spöttl, G., & Auernhammer, C. J. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.018 · Cited by 127

Stalling the Engine of Resistance: Targeting Cancer Metabolism to Overcome Therapeutic Resistance

Butler, E. B., Zhao, Y., Muñoz‐Pinedo, C., Lu, J., & Tan, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3009 · Cited by 126

Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways

Katz, D., Lazar, A. J., & Lev, D. C. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001227 · Cited by 124

The splicing-factor oncoprotein SF2/ASF activates mTORC1

Karni, R., Hippo, Y., Lowe, S. W., & Krainer, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801376105 · Cited by 122

Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma

Zheng, B., Mao, J., Lin, Q., Zhu, H., Gu, D., Pan, X., Fang, Y., & Ji, D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.012 · Cited by 123

Amino Acid Activation of mTORC1 by a PB1-Domain-Driven Kinase Complex Cascade

Linares, J. F., Durán, Á., Reina‐Campos, M., Aza‐Blanc, P., Campos, A. R., Moscat, J., & Díaz-Meco, M. T. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.045 · Cited by 123

Crosstalk between Apoptosis and Autophagy: Molecular Mechanisms and Therapeutic Strategies in Cancer

El‐Khattouti, A., Selimović, D., Haïkel, Y., & Hassan, M. (2013) · Journal of Cell Death · doi:10.4137/jcd.s11034 · Cited by 125

Effect of consecutive repeated sprint and resistance exercise bouts on acute adaptive responses in human skeletal muscle

Coffey, V. G., Jemiolo, B., Edge, J., Garnham, A. P., Trappe, S. W., & Hawley, J. A. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00351.2009 · Cited by 120

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

Garcia, J. A., & Danielpour, D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2408 · Cited by 120

B55β-Associated PP2A Complex Controls PDK1-Directed Myc Signaling and Modulates Rapamycin Sensitivity in Colorectal Cancer

Tan, J. Y., Lee, P. L., Li, Z., Jiang, X., Lim, Y. C., Hooi, S. C., & Yu, Q. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.021 · Cited by 119

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies

Wise-Draper, T. M., Moorthy, G., Salkeni, M. A., Karim, N. A., Thomas, H. E., Mercer, C. A., Beg, M. S., O’Gara, S., Olowokure, O. O., Fathallah, H., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0482-9 · Cited by 120

T Cell Receptor–Dependent Activation of mTOR Signaling in T Cells Is Mediated by Carma1 and MALT1, But Not Bcl10

Hamilton, K. S., Phong, B. L., Corey, C. G., Cheng, J., Gorentla, B. K., Zhong, X., Shiva, S., & Kane, L. (2014) · Science Signaling · doi:10.1126/scisignal.2005169 · Cited by 124

Rapamycin regulates Akt and ERK phosphorylation through mTORC1 and mTORC2 signaling pathways

Chen, X., Liu, F., Song, X., Wang, Z., Dong, Z., Hu, Z., Lan, R., Guan, W., Zhou, T., Xu, X., et al. (2010) · Molecular Carcinogenesis · doi:10.1002/mc.20628 · Cited by 123

Conditional genetic deletion of PTEN after a spinal cord injury enhances regenerative growth of CST axons and motor function recovery in mice

Danilov, C. A., & Steward, O. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.02.012 · Cited by 118

CDK4/6-inhibiting drug substitutes for p21 and p16 in senescence: Duration of cell cycle arrest and MTOR activity determine geroconversion

Leontieva, O. V., & Blagosklonny, M. V. (2013) · Cell Cycle · doi:10.4161/cc.26130 · Cited by 122

mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia

Krymskaya, V. P., Snow, J., Cesarone, G., Khavin, I., Goncharov, D. A., Lim, P. N., Veasey, S. C., Ihida‐Stansbury, K., Jones, P. L., & Goncharova, E. A. (2011) · The FASEB Journal · doi:10.1096/fj.10-175018 · Cited by 116

Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects

Jhanwar‐Uniyal, M., Amin, A. G., Cooper, J., Das, K., Schmidt, M. H., & Murali, R. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2016.12.001 · Cited by 121

The role of autophagy in liver cancer: Molecular mechanisms and potential therapeutic targets

Cui, J., Gong, Z., & Shen, H. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.02.003 · Cited by 116

[18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy

Ma, W. W., Jacene, H. A., Song, D., Vilardell, F., Messersmith, W. A., Laheru, D. A., Wahl, R. L., Endres, C., Jimeno, A., Pomper, M. G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8383 · Cited by 116

Therapeutic targeting of the mTOR ‐signalling pathway in cancer: benefits and limitations

Moschetta, M., Reale, A., Marasco, C., Vacca, A., & Carratù, M. R. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12749 · Cited by 119

Signaling cross-talk in the resistance to HER family receptor targeted therapy

Yamaguchi, H., Chang, S. H., Hsu, J. L., & Hung, M. (2013) · Oncogene · doi:10.1038/onc.2013.74 · Cited by 118

The Enigma of Rapamycin Dosage

Mukhopadhyay, S., Frías, M. A., Chatterjee, A., Yellen, P., & Foster, D. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0720 · Cited by 116

Pharmacokinetics and Pharmacodynamics of Broccoli Sprouts on the Suppression of Prostate Cancer in Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) Mice: Implication of Induction of Nrf2, HO-1 and Apoptosis and the Suppression of Akt-dependent Kinase Pathway

Keum, Y., Khor, T. O., Lin, W., Shen, G., Kwon, K. H., Barve, A., Li, W., & Kong, A. N. T. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9948-5 · Cited by 114

Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma

Albiges, L. K., Chamming’s, F., Duclos, B., Stern, M., Motzer, R. J., Ravaud, A., & Camus, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds115 · Cited by 113

Amino acid management in cancer

Tsun, Z.-Y., & Possemato, R. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.08.002 · Cited by 120

Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model

Sun, Z., Zhang, L., Hall, B., Bian, Y., Gutkind, J. S., & Kulkarni, A. B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1371 · Cited by 112

Global ischemia induces lysosomal-mediated degradation of mTOR and activation of autophagy in hippocampal neurons destined to die

Hwang, J.-Y., Gertner, M. J., Pontarelli, F., Court-Vazquez, B. L., Bennett, M. V. L., Ofengeim, D., & Zukin, R. S. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.140 · Cited by 113

Anticancer effects of oleuropein

Shamshoum, H., Vlavcheski, F., & Tsiani, E. (2017) · BioFactors · doi:10.1002/biof.1366 · Cited by 119

Metastatic Renal Cell Carcinoma: Many Treatment Options, One Patient

Rini, B. I. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9836 · Cited by 109

Coupling of Ribosome Synthesis and Translational Capacity with Cell Growth

Dai, X., & Zhu, M. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.04.010 · Cited by 109

S6K1-Mediated Disassembly of Mitochondrial URI/PP1γ Complexes Activates a Negative Feedback Program that Counters S6K1 Survival Signaling

Djouder, N., Metzler, S. C., Schmidt, A., Wirbelauer, C., Gstaiger, M., Aebersold, R. H., Heß, D., & Krek, W. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.08.010 · Cited by 107

mTOR: taking cues from the immune microenvironment

Delgoffe, G. M., & Powell, J. D. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03125.x · Cited by 110

Hypoxia-Induced Energy Stress Inhibits the mTOR Pathway by Activating an AMPK/REDD1 Signaling Axis in Head and Neck Squamous Cell Carcinoma

Schneider, A., Younis, R. H., & Gutkind, J. S. (2008) · Neoplasia · doi:10.1593/neo.08586 · Cited by 107

mTOR: Its Critical Role in Metabolic Diseases, Cancer, and the Aging Process

Marafie, S. K., Al‐Mulla, F., & Abubaker, J. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116141 · Cited by 119

Deforolimus (AP23573) a novel mTOR inhibitor in clinical development

Mita, M. M., Sankhala, K. K., Abdel-Karim, I., Mita, A. C., & Giles, F. J. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802556485 · Cited by 108

Global Transcriptome Abnormalities of the Eutopic Endometrium from Women with Adenomyosis

Herndon, C. N., Aghajanova, L., Balayan, S., Erikson, D., Barragan, F., Goldfien, G., Vo, K. C., Hawkins, S., & Giudice, L. C. (2016) · Reproductive Sciences · doi:10.1177/1933719116650758 · Cited by 106

PI3K/Akt/mTOR signaling in medullary thyroid cancer: a promising molecular target for cancer therapy

Manfredi, G. I., Dicitore, A., Gaudenzi, G., Caraglia, M., Persani, L., & Vitale, G. (2014) · Endocrine · doi:10.1007/s12020-014-0380-1 · Cited by 107

Sensitivity of Glioblastomas to Clinically Available MEK Inhibitors Is Defined by Neurofibromin 1 Deficiency

See, W. L., Tan, I., Mukherjee, J., Nicolaides, T. P., & Pieper, R. O. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0334 · Cited by 106

Mammalian Target of Rapamycin and S6 Kinase 1 Positively Regulate 6-thioguanine-Induced Autophagy

Zeng, X., & Kinsella, T. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6163 · Cited by 94

Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Upregulates Glucose Transporter 1 Transcription via the mTORC1/NF-κB Signaling Pathways

Zhang, J., Jia, L., Lin, W., Yip, Y. L., Lo, K. W., Lau, V. M. Y., Zhu, D., Tsang, C. M., Zhou, Y., Deng, W., et al. (2017) · Journal of Virology · doi:10.1128/jvi.02168-16 · Cited by 105

Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3

Zhang, B., Dong, S., Zhu, R., Hu, C., Hou, J., Li, Y., Zhao, Q., Shao, X., Bu, Q., Li, H., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4332 · Cited by 104

mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumours

Kasajima, A., Pavel, M., Darb‐Esfahani, S., Noske, A., Stenzinger, A., Sasano, H., Dietel, M., Denkert, C., Röcken, C., Wiedenmann, B. J., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0126 · Cited by 104

microRNA-200a downregulation in human glioma leads to Gαi1 over-expression, Akt activation, and cell proliferation

Liu, Y.-Y., Chen, M., Cheng, L., Zhang, Z.-Q., Yu, Z., Jiang, Q., Chen, G., & Cao, C. (2018) · Oncogene · doi:10.1038/s41388-018-0184-5 · Cited by 104

Signal transduction pathways in FSH regulation of rat Sertoli cell proliferation

Riera, M. F., Regueira, M., Galardo, M. N., Pellizzari, E. H., Meroni, S. B., & Cigorraga, S. B. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00477.2011 · Cited by 109

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Gupta, M., Hendrickson, A. E. W., Yun, S. S., Han, J., Schneider, P. A., Koh, B. D., Stenson, M. J., Wellik, L. E., Shing, J. C., Peterson, K. L., et al. (2011) · Blood · doi:10.1182/blood-2011-04-346601 · Cited by 103

Rapamycin Inhibits Polyglutamine Aggregation Independently of Autophagy by Reducing Protein Synthesis

King, M. A., Hands, S., Hafiz, F., Mizushima, N., Tolkovsky, A. M., & Wyttenbach, A. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.043398 · Cited by 120

Chemoprevention and Treatment of Experimental Cowden's Disease by mTOR Inhibition with Rapamycin

SQUARIZE, C. H., CASTILHO, R. M., & Gutkind, J. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0922 · Cited by 103

Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action

Durán, I., Lambea, J., Maroto, P., González-Larriba, J. L., Flores, L. E., Granados-Principal, S. M., Graupera, M., Sáez, B., Vivancos, A. P., & Casanovas, O. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0463-4 · Cited by 101

MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways

Oneyama, C., Ikeda, J., Okuzaki, D., Suzuki, K., Kanou, T., Shintani, Y., Morii, E., Okumura, M., Aozasa, K., & Okada, M. (2011) · Oncogene · doi:10.1038/onc.2011.63 · Cited by 103

Lysosomal Biology in Cancer

Fennelly, C., & Amaravadi, R. K. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6934-0_19 · Cited by 107

Structure–activity relations of leucine derivatives reveal critical moieties for cellular uptake and activation of mTORC1-mediated signaling

Nagamori, S., Wiriyasermkul, P., Okuda, S., Kojima, N., Hari, Y., Kiyonaka, S., Mori, Y., Tominaga, H., Ohgaki, R., & Kanai, Y. (2016) · Amino Acids · doi:10.1007/s00726-015-2158-z · Cited by 96

Promotion of Ovarian Follicle Growth following mTOR Activation: Synergistic Effects of AKT Stimulators

Cheng, Y., Kim, J., Li, X. X., & Hsueh, A. J. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117769 · Cited by 100

Bisphenol-A-induced inactivation of the p53 axis underlying deregulation of proliferation kinetics, and cell death in non-malignant human breast epithelial cells

Dairkee, S. H., Luciani-Torres, M. G., Moore, D. H., & Goodson, W. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs379 · Cited by 102

Neuronal RARβ Signaling Modulates PTEN Activity Directly in Neurons and via Exosome Transfer in Astrocytes to Prevent Glial Scar Formation and Induce Spinal Cord Regeneration

Goncalves, M. B. C. V., Malmqvist, T., Clarke, E. E., Hubens, C. J., Grist, J., Hobbs, C., Trigo, D., Risling, M., Angéria, M., Damberg, P., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1339-15.2015 · Cited by 99

TAK ‐228 (formerly MLN 0128), an investigational oral dual TORC 1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non‐Hodgkin lymphoma, or Waldenström's macroglobulinemia

Ghobrial, I. M., Siegel, D. S. D., Vij, R., Berdeja, J. G., Richardson, P. G. G., Neuwirth, R. B., Patel, C. G., Zohren, F., & Wolf, J. L. (2016) · American Journal of Hematology · doi:10.1002/ajh.24300 · Cited by 100

Functional Translatome Proteomics Reveal Converging and Dose-Dependent Regulation by mTORC1 and eIF2α

Klann, K., Tascher, G., & Münch, C. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.11.010 · Cited by 98

Current approach in the treatment of hepatocellular carcinoma

Rossi, L. (2010) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v2.i9.348 · Cited by 97

S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer

Nawroth, R., Stellwagen, F., Schulz, W. A., Stoehr, R., Hartmann, A., Krause, B. J., Gschwend, J. E., & Retz, M. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027509 · Cited by 99

Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer

Sridharan, S., & Basu, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041199 · Cited by 95

The Intercellular Metabolic Interplay between Tumor and Immune Cells

Wang, T., Liu, G., & Wang, R. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00358 · Cited by 96

Anti-tumor and anti-metastatic roles of cordycepin, one bioactive compound of Cordyceps militaris

Jin, Y. H., Meng, X. W., Qiu, Z., Su, Y., Yu, P., & Qu, P. (2018) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2018.05.016 · Cited by 100

MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer

Chen, M., Wei, M.-X., Han, J., Wu, X., Li, C., Wang, J., Shen, W., & Lu, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.07.017 · Cited by 97

Serine and one-carbon metabolism, a bridge that links mTOR signaling and DNA methylation in cancer

Zeng, J., Wu, W. K. K., Wang, H., & Li, X. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104352 · Cited by 96

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Westin, J. R. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.01.007 · Cited by 95

The eIF4E/eIF4G Interaction Inhibitor 4EGI-1 Augments TRAIL-Mediated Apoptosis through c-FLIP Down-regulation and DR5 Induction Independent of Inhibition of Cap-Dependent Protein Translation

Fan, S., Li, Y., Yue, P., Khuri, F. R., & Sun, S. (2010) · Neoplasia · doi:10.1593/neo.10144 · Cited by 94

Leptin activation of mTOR pathway in intestinal epithelial cell triggers lipid droplet formation, cytokine production and increased cell proliferation

Fazolini, N. P. B., Cruz, A. L. S., Werneck, M. B. F., Viola, J. P. B., Maya‐Monteiro, C. M., & Bozza, P. T. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1041684 · Cited by 99

Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

Johnston, S. R. D. (2015) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv212 · Cited by 92

Chondrocyte autophagy is stimulated by HIF-1 dependent AMPK activation and mTOR suppression

Bohensky, J., Leshinsky, S., Srinivas, V., & Shapiro, I. M. (2009) · Pediatric Nephrology · doi:10.1007/s00467-009-1310-y · Cited by 93

Autophagy genes as tumor suppressors

Liang, C., & Jung, J. U. (2009) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.003 · Cited by 99

Mitotic Raptor Promotes mTORC1 Activity, G2/M Cell Cycle Progression, and Internal Ribosome Entry Site-Mediated mRNA Translation

Ramírez‐Valle, F., Badura, M. L., Braunstein, S. E., Narasimhan, M., & Schneider, R. J. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00322-09 · Cited by 97

Reverse-Phase Protein Array Profiling of Oropharyngeal Cancer and Significance of PIK3CA Mutations in HPV-Associated Head and Neck Cancer

Sewell, A. B., Brown, B. T., Biktasova, A., Mills, G. B., Lu, Y., Tyson, D. R., Issaeva, N., & Yarbrough, W. G. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2585 · Cited by 93

Planarian PTEN homologs regulate stem cells and regeneration through TOR signaling

Oviedo, N. J., Pearson, B. J., Levin, M. G., & Alvarado, A. S. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000117 · Cited by 94

PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas

Nozhat, Z., & Hedayati, M. (2015) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-015-0175-y · Cited by 92

VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway

Villaume, K., Blanc, M., Gouysse, G., Walter, T., Couderc, C., Nejjari, M., Vercherat, C., Cordier–Bussat, M., Roche, C., & Scoazec, J. (2010) · Neuroendocrinology · doi:10.1159/000289569 · Cited by 92

Mammalian target of rapamycin as a therapeutic target in oncology

Abraham, R. T., & Eng, C. H. (2008) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.12.2.209 · Cited by 92

Inflammatory microenvironment in the initiation and progression of bladder cancer

Sui, X., Lei, L., Chen, L., Xie, T., & Li, X. (2017) · Oncotarget · doi:10.18632/oncotarget.21565 · Cited by 92

mRNA Translation and Energy Metabolism in Cancer: The Role of the MAPK and mTORC1 PathwaysPreprint

Topisirović, I., & Sonenberg, N. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2011.76.010785 · Cited by 96

Conventional and emerging roles of the energy sensor Snf1/AMPK in Saccharomyces cerevisiae

Coccetti, P., Nicastro, R., & Tripodi, F. (2018) · Microbial Cell · doi:10.15698/mic2018.11.655 · Cited by 99

Everolimus Inhibits Anti-HLA I Antibody-Mediated Endothelial Cell Signaling, Migration and Proliferation More Potently Than Sirolimus

Jin, Y., Valenzuela, N. M., Ziegler, M. E., Rozengurt, E., & Reed, E. F. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12669 · Cited by 91

Diminished Parkin Solubility and Co-Localization with Intraneuronal Amyloid-β are Associated with Autophagic Defects in Alzheimer's Disease

Lonskaya, I., Shekoyan, A. R., Hebron, M. L., Desforges, N. M., Algarzae, N. K., & Moussa, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121141 · Cited by 93

Emerging roles of PDGF-D in EMT progression during tumorigenesis

Wu, Q., Hou, X., Xia, J., Qian, X., Miele, L., Sarkar, F. H., & Wang, Z. P. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.11.006 · Cited by 92

mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice

Chen, X., Wang, Y., Tao, J., Shi, Y.-Z., Gai, X., Huang, F., Ma, Q., Zhou, Z., Chen, H., Zhang, H., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.005 · Cited by 89

mTORC1 Overactivation as a Key Aging Factor in the Progression to Type 2 Diabetes Mellitus

Guillén, C., & Benito, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00621 · Cited by 91

MYC Cooperates with AKT in Prostate Tumorigenesis and Alters Sensitivity to mTOR Inhibitors

Clegg, N. J., Couto, S. S., Wongvipat, J., Hieronymus, H., Carver, B. S., Taylor, B. S., Ellwood‐Yen, K., Gerald, W. L., Sander, C., & Sawyers, C. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017449 · Cited by 92

Autophagy Control by the VEGF-C/NRP-2 Axis in Cancer and Its Implication for Treatment Resistance

Stanton, M. J., Dutta, S., Zhang, H., Polavaram, N. S., Leontovich, A. A., Hönscheid, P., Sinicrope, F. A., Tindall, D. J., Muders, M. H., & Datta, K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3635 · Cited by 86

Rapamycin Prevents Early Onset of Tumorigenesis in an Oral-Specific K- ras and p53 Two-Hit Carcinogenesis Model

Raimondi, A. R., Molinolo, A., & Gutkind, J. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4645 · Cited by 88

Biochemical characterisation of TCTP questions its function as a guanine nucleotide exchange factor for Rheb

Rehmann, H., Brüning, M., Berghaus, C., Schwarten, M., Köhler, K., Stocker, H., Stoll, R., Zwartkruis, F. J. T., & Wittinghofer, A. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.07.057 · Cited by 88

Regulating Mammalian Target of Rapamycin To Tune Vaccination-Induced CD8+ T Cell Responses for Tumor Immunity

Li, Q., Rao, R. R., Vazzana, J., Goedegebuure, P. S., Odunsi, K. O., Gillanders, W. E., & Shrikant, P. A. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103365 · Cited by 89

Vitamin D3 Inhibits Wnt/β-Catenin and mTOR Signaling Pathways in Human Uterine Fibroid Cells

Al-Hendy, A. A., Diamond, M. P., Boyer, T., & Halder, S. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3555 · Cited by 88

Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study

Bee, J., Fuller, S., Miller, S., & Johnson, S. R. (2017) · Thorax · doi:10.1136/thoraxjnl-2017-210872 · Cited by 88

An mTORC1-Mdm2-Drosha Axis for miRNA Biogenesis in Response to Glucose- and Amino Acid-Deprivation

Ye, P., Liu, Y., Chen, C., Tang, F., Wu, Q., Wang, X., Liu, C.-G., Liu, X., Liu, R., Liu, Y., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.034 · Cited by 90

Sorafenib-Induced Apoptosis in Hepatocellular Carcinoma Is Reversed by SIRT1

Garten, A., Grohmann, T., Kľučková, K., Lavery, G. G., Kieß, W., & Penke, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20164048 · Cited by 86

PI3K/mTORC1 activation in hamartoma syndromes: Therapeutic prospects

Krymskaya, V. P., & Goncharova, E. A. (2009) · Cell Cycle · doi:10.4161/cc.8.3.7555 · Cited by 84

Targeting the translational machinery as a novel treatment strategy for hematologic malignancies

Hagner, P. R., Schneider, A., & Gartenhaus, R. B. (2010) · Blood · doi:10.1182/blood-2009-09-220020 · Cited by 89

Signaling From the Golgi: Mechanisms and Models for Golgi Phosphoprotein 3–Mediated Oncogenesis

Scott, K. L., & Chin, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1695 · Cited by 89

TAK1 mediates convergence of cellular signals for death and survival

Aashaq, S., Batool, A., & Andrabi, K. I. (2018) · APOPTOSIS · doi:10.1007/s10495-018-1490-7 · Cited by 86

Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS

Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 98

Mechanisms governing the control of mRNA translation

Livingstone, M., Atas, E., Meller, A., & Sonenberg, N. (2010) · Physical Biology · doi:10.1088/1478-3975/7/2/021001 · Cited by 88

Drug discovery targeting the mTOR pathway

Martelli, A. M., Buontempo, F., & McCubrey, J. A. (2018) · Clinical Science · doi:10.1042/cs20171158 · Cited by 77

TOR (target of rapamycin) as an anti-cancer target

Bousquet, G., Dreyer, C., Faivre, S. J., & Raymond, É. (2007) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2008.04.004 · Cited by 2

Mammalian Target of Rapamycin (mTOR) Signalling Pathway-A Potential Target for Cancer Intervention: A Short Overview

Basnet, R., Basnet, B. B., Gupta, R., Basnet, T. B., Khadka, S., & Alam, M. S. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230331081959 · Cited by 11

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Wander, S. A., Hennessy, B. T., & Slingerland, J. M. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44145 · Cited by 427

Unveiling the Role of Mechanistic Target of Rapamycin Kinase (MTOR) Signaling in Cancer Progression and the Emergence of MTOR Inhibitors as Therapeutic Strategies

Mehta, D., Rajput, K., Jain, D., Bajaj, A., & Dasgupta, U. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00530 · Cited by 25